GSK Takes Lupin To Court To Block Generic Combivir Launch in the U.S.
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Europe's largest drugmaker GlaxoSmithKline has sued Indian drug maker Lupin for infringement of its patents for anti-AIDS drug Combivir in the U.S
You may also be interested in...
Lupin Deal Spree Continues, Looks ‘Down Under’ For Generic Growth
MUMBAI - Three weeks after it announced the acquisition of German generic firm Hormosan, the world's largest manufacturer of anti-TB drugs - Lupin - has bought a minority stake in Australian drug maker Generic Health (PharmAsia News, July 31, 2008)
World's Largest TB Drug Maker Lupin Acquires German Generic Company Hormosan To Extend Reach Into Europe
MUMBAI - Lupin, the world's largest manufacturer of anti-TB drugs, has acquired German generics firm Hormosan Pharma GmbH to establish a "bridgehead" and sharpen its focus in the European market
Cipla Overtakes GSK to Become Top Indian Pharma Company (India)
So far in 2007, Cipla has emerged ahead of its competitors to become the top pharmaceutical company in the Indian domestic market with a share of 5.17 percent. Its closest competition is GlaxoSmithKline at 4.89 percent. Local leaders Ranbaxy, Nicholas Piramal, and Zydus Cadila followed up in the third, fourth, and fifth positions respectively. When international sales were taken into account, it was Ranbaxy that came out on top with the highest overall revenues of any Indian pharmaceutical manufacturer. Ranbaxy took the spot from Dr. Reddy's Laboratories, which held the lead position up until two months ago. (Click here for more